A new class in INTRAOCULAR LENS technology

Now Recruiting Patients for our AMD Study

Developing solutions to improve post-cataract surgery vision.

OnPoint Vision™ designs, develops and manufactures intraocular lenses intended to correct residual refractive error in patients who have already undergone cataract surgery as well as employ a strong interest in the treatment of patients who have experienced visual decline due to age-related retinal pathologies.

Our mission is to provide a highly differentiated minimally-invasive surgical solution designed to customize the visual outcome of the pseudophakic eye.

FDA request Cady to address macular degeneration with lens

OnPoint Vision Sees Clear Road Ahead

The Food and Drug Administration initially accepted Kevin Cady’s proposal for an implantable lens to correct vision after cataract surgery. Then the FDA switched course by asking Cady to consider a different unmet need—patients suffering from macular degeneration, with vision 20/80 or worse.

“I thought this wouldn’t help us,” Cady recalled. “But they did us a favor. They opened our eyes— there might be another population that this lens application can serve.”

Key Opinion Leaders Praise AccuraSee IOPCL Presentation at AECOS

OnPoint Vision president Kevin Cady was honored to present at the AECOS 2022 summer symposium. 

The AccuraSee IOPCL presentation scored high among the physician attendees.

Previous slide
Next slide
1st cadylens patient doing great over a year after implant
Implanted over a year ago, the very first CadyLens (aka AccuraSee™) implant patient is doing great!

Thanks to the skillful hands of Dr. Ralph Chu at Chu Vision Institute, Minneapolis, MN, we can all celebrate this great outcome and accomplishment!

President & CEO

Kevin Cady is the CEO and Founder of OnPoint Vision™, a refractive company that designs, develops & manufactures intraocular lens implants, most specifically the AccuraSee™ Intraocular Pseudophakic Contact Lens (AKA: CadyLens) designed to fine-tune the refractive error of the pseudophakic eye as well as deliver vision recovery for patients who have experienced a decline in vision due to age-related retinal pathologies.  Prior to forming OnPoint Vision™, Mr. Cady joined Refocus Group in 2015 as Vice President of Marketing & Business Development. From 2011 to 2014, Mr. Cady was the Regional Business Director for WaveTec Vision Systems, where he was responsible for the marketplace expansion of the Optiwave Refractive Analysis (ORA) system to ophthalmic surgeons. Prior to joining WaveTec Vision Systems, Mr. Cady was the Area Vice President of Sales for Bausch Lomb Surgical, after the company acquired Eyeonics. Mr. Cady has over 30 years in the ophthalmic industry theatre with extensive knowledge and experience in both the development of ophthalmic pharmacologic agents and medical device product line.

Mr. Cady has a Bachelor of Science Degree in Economics from Illinois State University. He is credentialed with over 35 patents worldwide with the  invention of the CadyLens, an Intraocular Pseudophakic Contact Lens (IOPCL) as well as related surgical instruments and medical devices.